CO6960542A2 - Polimorfos de inhibidores de cinasas - Google Patents

Polimorfos de inhibidores de cinasas

Info

Publication number
CO6960542A2
CO6960542A2 CO14051879A CO14051879A CO6960542A2 CO 6960542 A2 CO6960542 A2 CO 6960542A2 CO 14051879 A CO14051879 A CO 14051879A CO 14051879 A CO14051879 A CO 14051879A CO 6960542 A2 CO6960542 A2 CO 6960542A2
Authority
CO
Colombia
Prior art keywords
polymorphs
kinase inhibitors
kinase
inhibitors
Prior art date
Application number
CO14051879A
Other languages
English (en)
Spanish (es)
Inventor
Pingda Ren
Michael Martin
Original Assignee
Intellikine Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47669006&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6960542(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intellikine Llc filed Critical Intellikine Llc
Publication of CO6960542A2 publication Critical patent/CO6960542A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CO14051879A 2011-08-11 2014-03-11 Polimorfos de inhibidores de cinasas CO6960542A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161522624P 2011-08-11 2011-08-11

Publications (1)

Publication Number Publication Date
CO6960542A2 true CO6960542A2 (es) 2014-05-30

Family

ID=47669006

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14051879A CO6960542A2 (es) 2011-08-11 2014-03-11 Polimorfos de inhibidores de cinasas

Country Status (25)

Country Link
US (1) US20150065524A1 (https=)
EP (1) EP2741749A4 (https=)
JP (1) JP2014521726A (https=)
KR (1) KR20140079368A (https=)
CN (1) CN103957918A (https=)
AU (1) AU2012294202B2 (https=)
BR (1) BR112014003214A2 (https=)
CA (1) CA2844742A1 (https=)
CL (1) CL2014000343A1 (https=)
CO (1) CO6960542A2 (https=)
CR (1) CR20140082A (https=)
DO (1) DOP2014000027A (https=)
EA (1) EA027970B1 (https=)
EC (1) ECSP14013236A (https=)
HK (1) HK1199203A1 (https=)
IL (1) IL230850A0 (https=)
MX (1) MX2014001662A (https=)
MY (1) MY186267A (https=)
PE (1) PE20141358A1 (https=)
PH (1) PH12014500331A1 (https=)
RU (1) RU2636588C2 (https=)
SG (2) SG2014009492A (https=)
TN (1) TN2014000063A1 (https=)
WO (1) WO2013023184A1 (https=)
ZA (1) ZA201401211B (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004060403A2 (en) 2003-01-06 2004-07-22 Angiochem Inc. Aprotinin and anglos as carriers across the blood-brain barrier
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
WO2010043049A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Etoposide and doxorubicin conjugates for drug delivery
CA2740316A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Conjugates of glp-1 agonists and uses thereof
CA2745524C (en) 2008-12-05 2020-06-09 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
US8853353B2 (en) 2008-12-17 2014-10-07 Angiochem, Inc. Membrane type-1 matrix metalloprotein inhibitors and uses thereof
MX2011011023A (es) 2009-04-20 2012-01-20 Angiochem Inc Tratamiento de cancer de ovarios usando un agente anti-cancer conjugado con un analogo de angiopep-2.
RU2012103240A (ru) 2009-07-02 2013-08-10 Ангиокем Инк. Мультимерные пептидные конъюгаты и их применение
WO2013070976A1 (en) * 2011-11-08 2013-05-16 Intellikine, Llc Treatment regimens using multiple pharmaceutical agents
CN104250250A (zh) * 2013-06-25 2014-12-31 苏州科捷生物医药有限公司 4-芳香胺基嘧啶类化合物及其抗肿瘤用途
AU2014348657A1 (en) 2013-11-13 2016-05-19 Novartis Ag mTOR inhibitors for enhancing the immune response
ES2918501T3 (es) 2013-12-19 2022-07-18 Novartis Ag Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos
EP3087101B1 (en) 2013-12-20 2024-06-05 Novartis AG Regulatable chimeric antigen receptor
US20170335281A1 (en) 2014-03-15 2017-11-23 Novartis Ag Treatment of cancer using chimeric antigen receptor
AU2015244039B2 (en) 2014-04-07 2021-10-21 Novartis Ag Treatment of cancer using anti-CD19 chimeric antigen receptor
TWI719942B (zh) 2014-07-21 2021-03-01 瑞士商諾華公司 使用cd33嵌合抗原受體治療癌症
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
JP2017528433A (ja) 2014-07-21 2017-09-28 ノバルティス アーゲー 低い免疫増強用量のmTOR阻害剤とCARの組み合わせ
EP4205749A1 (en) 2014-07-31 2023-07-05 Novartis AG Subset-optimized chimeric antigen receptor-containing cells
AU2015301460B2 (en) 2014-08-14 2021-04-08 Novartis Ag Treatment of cancer using GFR alpha-4 chimeric antigen receptor
MX2017002205A (es) 2014-08-19 2017-08-21 Novartis Ag Receptor quimerico de antigeno (car) anti-cd123 para uso en el tratamiento de cancer.
JP6839074B2 (ja) 2014-09-17 2021-03-03 ノバルティス アーゲー 養子免疫療法のためのキメラ受容体での細胞毒性細胞のターゲティング
KR20170068504A (ko) 2014-10-08 2017-06-19 노파르티스 아게 키메라 항원 수용체 요법에 대한 치료 반응성을 예측하는 바이오마커 및 그의 용도
ES2876974T3 (es) 2015-04-07 2021-11-15 Novartis Ag Combinación de terapia con receptor de antígeno quimérico y derivados de amino pirimidina
AU2016249005B2 (en) 2015-04-17 2022-06-16 Novartis Ag Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
EP3286211A1 (en) 2015-04-23 2018-02-28 Novartis AG Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
EP3307326B9 (en) 2015-06-15 2021-02-24 Angiochem Inc. Methods for the treatment of leptomeningeal carcinomatosis
ES2636646B1 (es) * 2016-04-05 2018-08-03 Universidade De Santiago De Compostela NUEVOS VEHÍCULOS PARA LA TRANSFECCIÓN DE miRNAs
EP3487878A4 (en) 2016-07-20 2020-03-25 University of Utah Research Foundation CD229-CAR-T CELLS AND METHOD FOR USE THEREOF
BR112019006781A2 (pt) 2016-10-07 2019-07-30 Novartis Ag receptores de antígeno quiméricos para o tratamento de câncer
BR112019010511A2 (pt) 2016-11-23 2019-09-17 Bayer Ag derivados de heterociclo bicíclico fundido como pesticidas
EP3615055A1 (en) 2017-04-28 2020-03-04 Novartis AG Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
PL3737685T3 (pl) * 2018-01-09 2023-10-02 Halcyon Labs Private Limited Sposób wytwarzania kryzaborolu i jego związków pośrednich
WO2019210153A1 (en) 2018-04-27 2019-10-31 Novartis Ag Car t cell therapies with enhanced efficacy
EP3788369A1 (en) 2018-05-01 2021-03-10 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW370529B (en) * 1992-12-17 1999-09-21 Pfizer Pyrazolopyrimidines
US7420084B2 (en) * 2002-07-18 2008-09-02 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US8476431B2 (en) * 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
ES2637113T3 (es) * 2011-01-10 2017-10-10 Infinity Pharmaceuticals, Inc. Procedimientos para preparar isoquinolinonas y formas sólidas de isoquinolinonas

Also Published As

Publication number Publication date
ZA201401211B (en) 2015-12-23
EP2741749A4 (en) 2015-04-15
EA027970B1 (ru) 2017-09-29
CA2844742A1 (en) 2013-02-14
SG2014009492A (en) 2014-09-26
HK1199203A1 (en) 2015-06-26
WO2013023184A1 (en) 2013-02-14
RU2014109023A (ru) 2015-09-20
PE20141358A1 (es) 2014-10-12
CN103957918A (zh) 2014-07-30
DOP2014000027A (es) 2014-07-15
AU2012294202A1 (en) 2014-03-06
MX2014001662A (es) 2014-08-26
MY186267A (en) 2021-07-01
PH12014500331A1 (en) 2014-03-31
IL230850A0 (en) 2014-03-31
CR20140082A (es) 2014-06-03
CL2014000343A1 (es) 2014-10-17
US20150065524A1 (en) 2015-03-05
JP2014521726A (ja) 2014-08-28
SG10201606288TA (en) 2016-09-29
EA201490446A1 (ru) 2014-05-30
TN2014000063A1 (en) 2015-07-01
BR112014003214A2 (pt) 2017-03-14
EP2741749A1 (en) 2014-06-18
KR20140079368A (ko) 2014-06-26
ECSP14013236A (es) 2014-06-30
NZ622208A (en) 2016-04-29
RU2636588C2 (ru) 2017-11-24
AU2012294202B2 (en) 2017-02-23

Similar Documents

Publication Publication Date Title
CO6960542A2 (es) Polimorfos de inhibidores de cinasas
EP2683693A4 (en) ROR-GAMMA-T INHIBITORS
EP2694517A4 (en) PROTEIN KINASE INHIBITORS
EP2710007A4 (en) Kinase inhibitors
EP2685986A4 (en) Glucosylceramide SYNTHASE INHIBITORS
EP2822935A4 (en) INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK)
SMT201700109B (it) Inibitori di istone demetilasi
CO6970602A2 (es) Inhibidores de quinasa
SMT201600238B (it) Inibitori di protein chinasi
SMT201600108B (it) Derivato di pirazochinolina come inibitori di pde9
CO6920291A2 (es) 3-pirmidin-4-il-oxazolidin-2-onas como inhibidores de la idhmutante
CO6831983A2 (es) Compuestos heterocíclicos como inhibidores de cinasas
CO7010824A2 (es) Inhibidores de aplicación viral
HRP20170112T8 (hr) Supstituirani spojevi piridin-2-karboksamida kao kinazni inhibitori signalne regulacije apoptoze
LT3181567T (lt) Pirazolpirimidino junginiai kaip kinazės slopikliai
IL230561A0 (en) Inhibitors of bruton's tyrosine kinsae
CO6880068A2 (es) Aminoquinazolinas como inhibidores de quinasa
IL228108A0 (en) Triazolopyridine compounds as pim kinase inhibitors
BR112014003878A2 (pt) síntese de r-bifenilalaninol
BR112014013850A2 (pt) conjunto de prateleiras
SMT201600001B (it) Imidazopiridazine come inibitori di akt chinasi
SMT201600328B (it) Nuovi composti come inibitori di diacilglicerolo aciltransferasi
EP2782579A4 (en) PYRAZINKINASEINHIBITOREN
EP2776428A4 (en) KINASEHEMMERPOLYMORPHE
EP2758387A4 (en) Pyridine compounds as kinase inhibitors